|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM376674830 |
| 003 |
DE-627 |
| 005 |
20241003233301.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240825s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202408511
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1556.xml
|
| 035 |
|
|
|a (DE-627)NLM376674830
|
| 035 |
|
|
|a (NLM)39180264
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Lan, Jinshuai
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Biomimetic Nanomodulators With Synergism of Photothermal Therapy and Vessel Normalization for Boosting Potent Anticancer Immunity
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 03.10.2024
|
| 500 |
|
|
|a Date Revised 03.10.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Combination therapy using photothermal therapy (PTT) and immunotherapy is one of the most promising approaches for eliciting host immune responses to ablate tumors. However, its therapeutic efficacy is limited due to inefficient immune cell infiltration and cellular immune responses. In this study, a biomimetic immunostimulatory nanomodulator, TmPDA-GA (4T1 membrane@polydopamine-gambogic acid), with homologous targeting is developed. The 4T1 membrane (Tm) coating reduced immunogenicity and facilitated uptake of Tm@PDA-GA by tumor cells. Polydopamine (PDA) as a drug carrier can induce PTT under near-infrared ray (NIR) irradiation and immunogenic cell death (ICD) to activate dendritic cells (DCs). Moreover, Tm@PDA-GA on-demand released gambogic acid (GA) in an acidic tumor microenvironment, inhibiting the expression of heat shock proteins (HSPs) for synergetic chemo-photothermal anti-tumor activity and increasing the ICD of 4T1 cells. More importantly, GA can normalize the vessels via HIF-1α and VEGF inhibition to enhance immune infiltration and alleviate hypoxia stress. Thus, Tm@PDA-GA induced ICD, activated DCs, stimulated cytotoxic T cells, and suppressed Tregs. Moreover, Tm@PDA-GA is combined with anti-PD-L1 to further augment the tumor immune response and effectively suppress tumor growth and lung metastasis. In conclusion, biomaterial-mediated PTT combined with vessel normalization is a promising strategy for effective immunotherapy of triple-negative breast cancer (TNBC)
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a PDA
|
| 650 |
|
4 |
|a immunotherapy
|
| 650 |
|
4 |
|a photothermal therapy
|
| 650 |
|
4 |
|a triple‐negative breast cancer
|
| 650 |
|
4 |
|a vessel normalization
|
| 650 |
|
7 |
|a Xanthones
|2 NLM
|
| 650 |
|
7 |
|a polydopamine
|2 NLM
|
| 650 |
|
7 |
|a Indoles
|2 NLM
|
| 650 |
|
7 |
|a gambogic acid
|2 NLM
|
| 650 |
|
7 |
|a 8N585K83U2
|2 NLM
|
| 650 |
|
7 |
|a Polymers
|2 NLM
|
| 650 |
|
7 |
|a Drug Carriers
|2 NLM
|
| 700 |
1 |
|
|a Zeng, Ruifeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Zhe
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Xuguang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Li
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Lixia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Liyan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shen, Yi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Tong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ding, Yue
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 40 vom: 22. Okt., Seite e2408511
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:40
|g day:22
|g month:10
|g pages:e2408511
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202408511
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 40
|b 22
|c 10
|h e2408511
|